BioCentury | Oct 25, 2019
Product Development

Deciding factors in the shifting MS treatment landscape

...dosed daily, and Tecfidera is dosed twice daily. “The most effective treatments for MS are natalizumab...
...chair of clinical research and co-director of the Rocky Mountain Multiple Sclerosis Center. Biogen’s Tysabri natalizumab...
BioCentury | Sep 19, 2019
Product Development

Anokion puts liver to the test

...2 and improved to 1 by day 17. Biogen Inc. (NASDAQ:BIIB) markets anti-VLA-4 mAb Tysabri natalizumab...
...MOG - Myelin oligodendrocyte glycoprotein VLA-4 (CD49D) - Integrin alpha(4) Allison Johnson, Senior Writer Tysabri, natalizumab (AN100226, Antegren) Biogen...
BioCentury | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

...handily topping consensus estimates of $7.53 and $3.47 billion. MS therapies Tecfidera dimethyl fumarate, Tysabri natalizumab...
BioCentury | Mar 15, 2019
Company News

Fujifilm buying Biogen’s Denmark manufacturing site for $890M

...which will use the Hillerød site to produce commercial products for Biogen, such as Tysabri natalizumab...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...darbepoetin alfa $2,053.0 $1,403.0 $1,870.7 -9% Biogen Inc. (NASDAQ:BIIB) / Eisai Co. Ltd. (Tokyo:4523) Tysabri natalizumab...
BioCentury | Dec 7, 2018
Tools & Techniques

Filaments line up as MS biomarker

...The presentations included statistically significant reductions in blood levels of NEFL after treatment with Tysabri natalizumab...
...from Biogen, Campath-1H alemtuzumab from Sanofi and Copaxone glatiramer acetate from Teva Pharmaceutical Industries Ltd. “Tysabri...
BioCentury | Mar 30, 2018
Clinical News

Northwestern researchers report Phase III MS data for HSCT vs. continuing disease-modifying therapies

...Marrow Transplantation (EBMT) meeting in Lisbon. Disease-modifying therapies used in the control arm included Tysabri natalizumab...
...Imusera, fingolimod (FTY720, TDI-132) Novantrone (Brand), mitoxantrone (Generic), Novantrone (Other) Tecfidera, dimethyl fumarate (bg-12, BG00012) Tysabri, natalizumab (AN100226, Antegren) Northwestern...
BioCentury | Feb 9, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...in the indication. Biogen markets natalizumab, a humanized mAb against integrin alpha(4) (VLA-4; CD49D), as Tysabri...
...treatment with 300 or 600 mg natalizumab or placebo. On the trial's primary endpoint, IV natalizumab...
...cerebral edema (see BioCentury, May 19, 2017 ). Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Product: Tysabri natalizumab...
BioCentury | Feb 7, 2018
Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

...Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed...
...in the indication. Biogen markets natalizumab, a humanized mAb against integrin alpha(4) (VLA-4; CD49D), as Tysabri...
...treatment with 300 or 600 mg natalizumab or placebo. On the trial's primary endpoint, IV natalizumab...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...7% Amgen Inc. (NASDAQ:AMGN) Aranesp darbepoetin alfa $2,093.0 $1,562.0 $2,082.7 0% Biogen Inc. (NASDAQ:BIIB) Tysabri natalizumab...
Items per page:
1 - 10 of 801